Baolingbao Biology Co Ltd (002286) - Total Assets
Based on the latest financial reports, Baolingbao Biology Co Ltd (002286) holds total assets worth CN¥2.73 Billion CNY (≈ $400.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 002286 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Baolingbao Biology Co Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Baolingbao Biology Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore Baolingbao Biology Co Ltd (002286) long-term investment share to see how much of total assets are deployed in long-term investments.
Baolingbao Biology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Baolingbao Biology Co Ltd's total assets of CN¥2.73 Billion consist of 30.3% current assets and 69.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.5% |
| Accounts Receivable | CN¥253.85 Million | 9.5% |
| Inventory | CN¥288.71 Million | 10.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥117.50 Million | 4.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Baolingbao Biology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002286 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Baolingbao Biology Co Ltd's current assets represent 30.3% of total assets in 2024, a decrease from 50.2% in 2006.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2024, down from 23.7% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 11.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 10.8% of total assets.
Baolingbao Biology Co Ltd Competitors by Total Assets
Key competitors of Baolingbao Biology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Palvella Therapeutics, Inc
NASDAQ:PVLA
|
USA | $263.76 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
USA | $282.61 Million |
Baolingbao Biology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.83 | 1.46 | 1.05 |
| Quick Ratio | 1.31 | 1.00 | 0.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥397.36 Million | CN¥270.24 Million | CN¥51.75 Million |
Baolingbao Biology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Baolingbao Biology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.82 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 0.6% |
| Total Assets | CN¥2.67 Billion |
| Market Capitalization | $497.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Baolingbao Biology Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Baolingbao Biology Co Ltd's assets grew by 0.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Baolingbao Biology Co Ltd (2006–2024)
The table below shows the annual total assets of Baolingbao Biology Co Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.67 Billion ≈ $391.29 Million |
+0.57% |
| 2023-12-31 | CN¥2.66 Billion ≈ $389.08 Million |
-11.55% |
| 2022-12-31 | CN¥3.01 Billion ≈ $439.89 Million |
-0.75% |
| 2021-12-31 | CN¥3.03 Billion ≈ $443.24 Million |
+15.80% |
| 2020-12-31 | CN¥2.62 Billion ≈ $382.76 Million |
+3.85% |
| 2019-12-31 | CN¥2.52 Billion ≈ $368.57 Million |
-2.35% |
| 2018-12-31 | CN¥2.58 Billion ≈ $377.43 Million |
+22.42% |
| 2017-12-31 | CN¥2.11 Billion ≈ $308.31 Million |
+9.08% |
| 2016-12-31 | CN¥1.93 Billion ≈ $282.65 Million |
+0.94% |
| 2015-12-31 | CN¥1.91 Billion ≈ $280.01 Million |
+8.35% |
| 2014-12-31 | CN¥1.77 Billion ≈ $258.44 Million |
+5.36% |
| 2013-12-31 | CN¥1.68 Billion ≈ $245.28 Million |
+50.63% |
| 2012-12-31 | CN¥1.11 Billion ≈ $162.83 Million |
+0.02% |
| 2011-12-31 | CN¥1.11 Billion ≈ $162.81 Million |
+7.75% |
| 2010-12-31 | CN¥1.03 Billion ≈ $151.10 Million |
-4.75% |
| 2009-12-31 | CN¥1.08 Billion ≈ $158.64 Million |
+45.73% |
| 2008-12-31 | CN¥743.91 Million ≈ $108.86 Million |
+23.59% |
| 2007-12-31 | CN¥601.90 Million ≈ $88.08 Million |
+18.50% |
| 2006-12-31 | CN¥507.93 Million ≈ $74.33 Million |
-- |
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and mal… Read more